Lynn Seely - Nov 16, 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
President and CEO, Director
Signature
/s/ Hector Casab, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Nov 16, 2023
Transactions value $
$0
Form type
4
Date filed
11/20/2023, 08:53 PM
Previous filing
Jun 23, 2023
Next filing
Feb 13, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Stock Option (right to buy) Award +7.5M 7.5M Nov 16, 2023 Common Stock 7.5M $1.87 Direct F1, F2, F3
transaction LYEL Stock Option (right to buy) Disposed to Issuer -7.5M -100% 0 Nov 16, 2023 Common Stock 7.5M $3.28 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty percent of the shares shall vest on December 15, 2023 and 1/60th of the total shares vest in equal monthly installments over the following forty-eight months.
F2 The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on November 16, 2023 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date.
F3 Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options.
F4 Twenty-five percent of the shares shall vest on December 15, 2023 and 1/48th of the shares vest in equal monthly installments over the following thirty-six months.